Farxiga for Type 2 Diabetes: Evidence, Dosing, and Clinical Use

What Is Dapagliflozin and How Does It Work?

Dapagliflozin blocks SGLT2 receptors in the renal proximal tubule, preventing glucose reabsorption and causing roughly 70 to 80 grams of glucose to be excreted in urine each day. This insulin-independent mechanism lowers blood glucose, reduces caloric load, and drives modest osmotic diuresis. Because the mechanism bypasses pancreatic beta cells entirely, hypoglycemia risk as monotherapy is low.

The kidneys normally reabsorb nearly all filtered glucose through SGLT2 and SGLT1 transporters. Dapagliflozin selectively inhibits SGLT2, which handles approximately 90% of renal glucose reabsorption [1]. The resulting glucosuria yields a caloric deficit of roughly 280 kcal per day, contributing directly to the weight loss seen in clinical trials.

Osmotic diuresis from glucosuria also reduces plasma volume and lowers systolic blood pressure by approximately 3 to 4 mmHg, an effect that may contribute to cardiovascular benefit independent of glucose lowering [2]. Tubuloglomerular feedback changes induced by SGLT2 inhibition reduce intraglomerular pressure, which underpins the drug's renal-protective effects observed in separate CKD trials [3].

The drug is taken orally once daily, with or without food. It reaches peak plasma concentration (Tmax) within 1 to 2 hours and has a half-life of approximately 12.9 hours, supporting once-daily dosing [4].

FDA Approval Status for Type 2 Diabetes

The FDA approved dapagliflozin for type 2 diabetes in adults on January 8, 2014, under the brand name Farxiga [5]. The approval was based on a broad clinical development program spanning more than 20 placebo- and active-controlled trials across different background therapies, including metformin, sulfonylureas, insulin, and combinations thereof.

The prescribing label requires that eGFR be assessed before initiation. Glycemic benefit is substantially reduced when eGFR falls below 45 mL/min/1.73 m², and the drug should not be started at that threshold for glucose-lowering purposes [5]. The label also carries a boxed warning against use in type 1 diabetes outside of a separate approved indication, given risk of diabetic ketoacidosis (DKA).

A subsequent supplemental approval in 2020 extended the indication to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF), with or without type 2 diabetes [5]. In 2021, a further approval covered adults with CKD at risk of progression.

Glycemic Efficacy: What the Trials Show

Across the clinical development program, dapagliflozin 10 mg reduced HbA1c by approximately 0.8 to 1.0 percentage points versus placebo after 24 weeks when added to background therapy [6]. Fasting plasma glucose fell by roughly 25 to 30 mg/dL, and body weight declined by 2 to 3 kg.

The DECLARE-TIMI 58 trial (N=17,160) is the largest cardiovascular outcomes trial for dapagliflozin in type 2 diabetes [7]. Patients had either established atherosclerotic cardiovascular disease or multiple cardiovascular risk factors. Over a median follow-up of 4.2 years, dapagliflozin did not increase major adverse cardiovascular events (MACE) and significantly reduced the composite of cardiovascular death or hospitalization for heart failure by 17% (hazard ratio 0.83 to 95% CI 0.73 to 0.95, P<0.005) [7]. The HbA1c difference between arms was modest at approximately 0.4 percentage points, suggesting that much of the cardiovascular benefit is not purely glucose-mediated.

A head-to-head trial published in Diabetes Care (N=814) compared dapagliflozin 10 mg with glipizide as add-on to metformin over 52 weeks [8]. Both drugs produced similar HbA1c reductions (approximately 0.52 percentage points), but dapagliflozin patients lost a mean of 3.2 kg while glipizide patients gained 1.4 kg. Hypoglycemia occurred in 40.8% of the glipizide group versus 3.5% in the dapagliflozin group [8].

In a 24-week trial (N=546) evaluating dapagliflozin as add-on to insulin in type 2 diabetes, the 10 mg dose reduced HbA1c by an additional 0.79 percentage points versus placebo and allowed a mean daily insulin dose reduction of 8.2 units [9].

Cardiovascular and Heart Failure Evidence

The DAPA-HF trial (N=4,744) enrolled adults with HFrEF (ejection fraction <40%), with 45% having type 2 diabetes [10]. Dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo (hazard ratio 0.74 to 95% CI 0.65 to 0.85, P<0.001) [10]. The benefit was consistent whether or not patients had diabetes at baseline, establishing that the mechanism extends beyond glucose lowering.

The 2023 ADA Standards of Care state: "In patients with type 2 diabetes and established heart failure, an SGLT2 inhibitor with proven benefit is recommended to reduce risk of worsening heart failure and cardiovascular death" [11]. Dapagliflozin is one of two SGLT2 inhibitors specifically named in that recommendation.

An individual patient-level meta-analysis of SGLT2 inhibitor cardiovascular outcomes trials published in The Lancet (2019, N=34,322 pooled) found a consistent 23% reduction in hospitalization for heart failure across agents (rate ratio 0.77 to 95% CI 0.71 to 0.84) [12]. The analysis confirmed that cardiovascular benefit was not significantly modified by baseline HbA1c, supporting use in patients across the glycemic spectrum.

Renal Protection in Type 2 Diabetes

The DAPA-CKD trial (N=4,304) enrolled patients with CKD stages 2 to 4 and albuminuria, 67.5% of whom had type 2 diabetes [3]. Dapagliflozin 10 mg reduced the composite of sustained 50% or greater decline in eGFR, end-stage kidney disease, or renal or cardiovascular death by 39% versus placebo (hazard ratio 0.61 to 95% CI 0.51 to 0.72, P<0.001) [3]. The trial was stopped early by the data safety monitoring board due to overwhelming efficacy.

ADA and KDIGO 2022 joint guidance recommends SGLT2 inhibitors, including dapagliflozin, for patients with type 2 diabetes and CKD who have eGFR of 25 mL/min/1.73 m² or greater and urine albumin-to-creatinine ratio of 200 mg/g or greater [13]. The renal protective mechanism operates even when eGFR is below the threshold where glycemic benefit diminishes.

The 2022 KDIGO guideline states: "We recommend treatment with an SGLT2 inhibitor for patients with type 2 diabetes and CKD who have eGFR ≥20 mL/min/1.73 m²" [13]. This represents a significant expansion from earlier guidance that restricted use at lower eGFR.

Dosing and Administration

The standard starting dose of dapagliflozin for type 2 diabetes is 5 mg once daily, taken in the morning with or without food [5]. If additional glycemic control is needed and the 5 mg dose is tolerated, it may be uptitrated to 10 mg once daily.

The 10 mg dose is required for heart failure and CKD indications [5]. Renal function should be assessed before initiation and periodically thereafter.

Dose adjustments are not required for hepatic impairment unless severe (Child-Pugh class C), where caution is warranted. No dose adjustment is needed for mild to moderate renal impairment, but glycemic efficacy decreases progressively as eGFR falls below 60 mL/min/1.73 m² [4].

Patients should be counseled to maintain adequate hydration, particularly during illness, excessive heat, or procedures requiring fasting, to reduce risk of volume depletion and acute kidney injury.

Drug Interactions and Contraindications

Dapagliflozin should not be used in type 1 diabetes outside of a dedicated trial or approved protocol, given DKA risk [5]. It is contraindicated in patients with a history of serious hypersensitivity to dapagliflozin or any excipient.

Concomitant use with insulin or insulin secretagogues (sulfonylureas, meglitinides) increases hypoglycemia risk; dose reduction of the secretagogue or insulin may be needed [5]. Diuretics combined with dapagliflozin can amplify volume depletion; monitor blood pressure and renal function if combining [14].

Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce renal function in volume-depleted patients taking dapagliflozin, increasing the risk of acute kidney injury [14]. Rifampin and other strong CYP3A4 inducers lower dapagliflozin exposure by approximately 22%, though this is unlikely to require dose adjustment in most patients [4].

Side Effects Relevant to Type 2 Diabetes Patients

Genital mycotic infections are the most common treatment-emergent adverse event, affecting approximately 8.4% of women and 2.7% of men in the dapagliflozin 10 mg arm versus 1.5% and 0.5% in the placebo arm, respectively, across pooled phase 3 data [6]. Most infections are mild and respond to standard antifungal therapy.

Urinary tract infections (UTIs) occurred at a numerically higher rate with dapagliflozin than placebo in early trials, though the difference was modest and not consistently significant across the entire development program [6]. Patients with recurrent UTIs may require closer monitoring.

Volume depletion symptoms including dizziness, orthostatic hypotension, and syncope occurred in approximately 1.1% of the 10 mg group versus 0.7% placebo in the development program [5]. Elderly patients and those on loop diuretics are at highest risk.

Diabetic ketoacidosis (DKA), including euglycemic DKA where blood glucose may be only modestly elevated, has been reported. Risk factors include prolonged fasting, surgery, excessive alcohol use, and low-carbohydrate diets [15]. The FDA issued a safety communication on euglycemic DKA in 2015 [15]. Patients should be instructed to hold dapagliflozin at least 3 to 4 days before elective surgery or procedures.

Fournier's gangrene (necrotizing fasciitis of the perineum) has been reported rarely across the SGLT2 class. An FDA safety review through 2018 identified 12 cases in postmarketing reports, with six of those 12 occurring in dapagliflozin users [16]. This is rare but requires prompt surgical evaluation if suspected.

Lower limb amputation was a safety signal identified with canagliflozin (CANVAS trial) but was not replicated with dapagliflozin in DECLARE-TIMI 58, where amputation rates were similar between arms [7].

Monitoring Parameters

Baseline assessment before starting dapagliflozin should include eGFR and urinalysis, HbA1c, blood pressure, and assessment for volume depletion [5]. Renal function should be checked approximately 4 weeks after initiation and then every 3 to 6 months depending on baseline eGFR [13].

HbA1c response is typically assessable at the 3-month mark. In the key add-on to metformin trial (N=546, 24-week duration), significant separation from placebo was evident by week 8 [6]. Full glycemic benefit is generally established by 12 weeks.

Blood pressure may decrease by 3 to 4 mmHg systolic within the first 4 to 6 weeks; antihypertensive doses may need adjustment to avoid hypotension [2].

Positioning Within the ADA Treatment Algorithm

The 2024 ADA Standards of Care position SGLT2 inhibitors, including dapagliflozin, as preferred add-on agents (alongside GLP-1 receptor agonists) in adults with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or CKD, independent of HbA1c level [11]. For patients without those comorbidities, dapagliflozin remains an option after metformin when additional glucose-lowering is needed, selected based on cost, tolerability, and patient preference.

The ADA algorithm explicitly states: "For patients with type 2 diabetes and heart failure, SGLT2 inhibitors are recommended to reduce heart failure hospitalization and cardiovascular mortality" [11]. This recommendation carries Level A evidence (from multiple well-conducted randomized controlled trials).

Dapagliflozin can be combined with metformin, GLP-1 receptor agonists, DPP-4 inhibitors, insulin, or sulfonylureas. Fixed-dose combination tablets pairing dapagliflozin 5 mg or 10 mg with metformin extended-release (Xigduo XR) are available and FDA-approved, which may reduce pill burden for appropriate patients [5].

Cost, Access, and Insurance Coverage

Farxiga carries a list price of approximately $600 to $650 per month for a 30-tablet supply of 10 mg in the United States as of late 2023. Most major commercial insurance formularies list dapagliflozin at tier 2 or tier 3, with copays ranging from roughly $30 to $90 per month depending on plan [17].

Medicare Part D coverage varies by plan; many Advantage and standalone Part D plans include Farxiga, but prior authorization is sometimes required, particularly when metformin has not been documented as background therapy [17].

AstraZeneca's Farxiga Savings Card program can reduce out-of-pocket costs to as low as $10 per month for eligible commercially insured patients. Patient assistance programs are available for uninsured patients meeting income criteria; details are maintained at the manufacturer's website and at NeedyMeds.org.

Generic dapagliflozin is not yet available in the United States as of the article's review date. The earliest potential generic entry depends on patent expiration timelines, which extend through at least 2025 for core composition-of-matter patents.

Special Populations

Elderly patients (65 years and older) show similar glycemic efficacy to younger adults, but the absolute HbA1c reduction may be slightly attenuated due to lower GFR-related glucosuria. Volume depletion risk is amplified, and a conservative approach to blood pressure management is recommended [5].

Patients with hepatic impairment (Child-Pugh class A or B) do not require dose adjustment, but exposure increases approximately 67% in severe hepatic impairment (Child-Pugh class C), and the drug should be used with caution or avoided in that group [4].

Pregnancy: dapagliflozin is not recommended during the second and third trimesters. Animal data show kidney dysplasia at exposures relevant to human therapeutic doses, and the FDA label includes warnings against use during pregnancy [5].